Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

This Protocol Focuses on the Factors That Influence Survival, the Development of Complications and the Quality of Life Based on the Treatment Received in the Group of Patients Suffering From Malignant Lesions of the Head and Neck

NCT07066878 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2026-05-01
Last updated
2025-07-15

Condition(s) studied

Head and Neck Cancer

Investigational drug(s) / intervention(s)

treatment received in the group of patients suffering from malignant lesions of the head and neck.

treatment received in the group of patients suffering from malignant lesions of the head and neck.: This protocol focuses on a retrospective, single-center analysis, analyzing the factors that influence survival as the main objective, and secondarily the development of complications and the quality of life based on the treatment received in the group of patients suffering from malignant lesions of the head and neck.

Study summary

This protocol focuses on a retrospective, single-center analysis, analyzing the factors that influence survival as the main objective, and secondarily the development of complications and the quality of life based on the treatment received in the group of patients suffering from malignant lesions of the head and neck.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Participant is willing and able to provide informed consent for study participation * Age 18 years or older * Histological diagnosis of head and neck cancer (any site, any histology) * Treatment (surgical and/or radiotherapy and/or medical) received at San Raffaele Hospital between January 2014 and January 2024 * Consent for use of personal data for scientific purposes Exclusion Criteria: * Age under 18 years * No histological diagnosis of head and neck cancer * Treatment not performed at San Raffaele Hospital (surgical and/or radiotherapy and/or medical) * Lack of signed consent for use of personal data for scientific purposes * Severe comorbidities interfering with study participation or treatment protocols * Inability to understand or provide informed consent due to cognitive or psychiatric disorders * Concurrent participation in another clinical trial that may interfere with study outcomes

Primary outcome measure(s)

  • Overall Survival (OS) in Patients with Head and Neck Malignancies Treated with Curative Intent — 5 years
    To assess overall survival in patients with malignant lesions of the head and neck (oral cavity, oropharynx, hypopharynx, larynx) undergoing curative treatment. Treatment modalities include major oncological surgery (alone or followed by adjuvant radiotherapy ± chemotherapy), definitive radiotherapy, definitive chemoradiotherapy, or induction chemotherapy followed by surgery or radiotherapy. Time Frame: 5 years from treatment initiation Unit of Measure: Time (months)

Trial sites (1)

FacilityCityRegionStatus
Ospedale San Raffaele Milan Italy
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07066878 on ClinicalTrials.gov ↗ ← All trials in Italy